Eric Sagonowsky

Editor

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in November 2014 and covers topics such as drug pricing, biosimilars and product liability litigation.

Stories by Eric Sagonowsky

Epizyme scores its first FDA nod for rare cancer med Tazverik

by Eric Sagonowsky

Friday, January 24, 2020

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

Pfizer eyes Roche blockbusters with 3 biosim launches

by Eric Sagonowsky

Friday, January 24, 2020

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Inovio, Moderna score CEPI funding for coronavirus work

by Eric Sagonowsky

Thursday, January 23, 2020

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

CAR-T damages at $1.5B? BMS demands more from Gilead patent win

by Eric Sagonowsky

Thursday, January 23, 2020

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.

J&J's expects last year's copycat pain to 'bleed into 2020'

by Eric Sagonowsky

Wednesday, January 22, 2020

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Vaccine researchers kick off work against new coronavirus

by Eric Sagonowsky

Tuesday, January 21, 2020

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

JPM: Merck turns to CMOs to help with Gardasil supply

by Eric Sagonowsky

Tuesday, January 21, 2020

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

J&J scores as trial judge cuts $8B Risperdal verdict to $6.8M

by Eric Sagonowsky

Tuesday, January 21, 2020

An $8 billion jury verdict against Johnson & Johnson raised eyebrows back in October, but the judge has now slashed damages to just $6.8 million.

Pricing remains the industry's top concern in 2020: report

by Eric Sagonowsky

Tuesday, January 21, 2020

Drug pricing remains the pharma industry's top concern in 2020, execs said in a survey, as political threats continue from Washington, D.C.

Bayer's 'tumor-agnostic' Vitrakvi rejected in England, Germany

by Eric Sagonowsky

Friday, January 17, 2020

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.